GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advaxis Inc (OTCPK:ADXS) » Definitions » EV-to-EBIT

Advaxis (Advaxis) EV-to-EBIT : 0.44 (As of May. 11, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Advaxis EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Advaxis's Enterprise Value is $-10.58 Mil. Advaxis's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-23.96 Mil. Therefore, Advaxis's EV-to-EBIT for today is 0.44.

The historical rank and industry rank for Advaxis's EV-to-EBIT or its related term are showing as below:

ADXS' s EV-to-EBIT Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.46
Current: 0.44

During the past 13 years, the highest EV-to-EBIT of Advaxis was 0.46. The lowest was 0.00. And the median was 0.00.

ADXS's EV-to-EBIT is not ranked
in the Biotechnology industry.
Industry Median: 9.43 vs ADXS: 0.44

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Advaxis's Enterprise Value for the quarter that ended in Mar. 2023 was $-9.21 Mil. Advaxis's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-23.96 Mil. Advaxis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 was 260.17%.


Advaxis EV-to-EBIT Historical Data

The historical data trend for Advaxis's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advaxis EV-to-EBIT Chart

Advaxis Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.92 -0.27 -1.54 1.34

Advaxis Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Mar23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 1.29 1.35 1.34 0.38

Competitive Comparison of Advaxis's EV-to-EBIT

For the Biotechnology subindustry, Advaxis's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advaxis's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Advaxis's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Advaxis's EV-to-EBIT falls into.



Advaxis EV-to-EBIT Calculation

Advaxis's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-10.580/-23.962
=0.44

Advaxis's current Enterprise Value is $-10.58 Mil.
Advaxis's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advaxis  (OTCPK:ADXS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Advaxis's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2023 ) =EBIT / Enterprise Value (Q: Mar. 2023 )
=-23.962/-9.210075
=260.17 %

Advaxis's Enterprise Value for the quarter that ended in Mar. 2023 was $-9.21 Mil.
Advaxis's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-23.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Advaxis EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Advaxis's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Advaxis (Advaxis) Business Description

Traded in Other Exchanges
N/A
Address
9 Deer Park Drive, Suite K-1, Monmouth Junction, NJ, USA, 8540
Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer.
Executives
Roy Golan officer: Chief Financial Officer 24 GOLDA MEIR ST., HOLON L3 5840425
Yuval Cabilly director C/O BIOSIGHT THERAPEUTICS, 4 HASADOT STREET, RAMAT HASHARON L3 4704348
Pini Orbach director C/O BIOSIGHT THERAPEUTICS, 3 HAYARDEN STREET, AIRPORT CITY L3 7019802
Bridget A Martell director C/O POINT BIOPHARMA GLOBAL INC., 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Israel Biotech Fund Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Israel Biotech Fund Gp Partners Ii, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Murray A Goldberg director 2030 MAIN STREET, SUITE 1500, IRVINE CA 92614
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Vered Bisker-leib director C/O COMPASS, 245 FIRST STREET, 3RD FLOOR, CAMBRIDGE MA 02142
Israel Biotech Fund I, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Amoon Growth Fund Limited Partnership 10 percent owner 34 YERUSHALAYIM RD., RAANANA L3 4350110
Israel Biotech Fund Gp Partners, L.p. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Yair Chaim Schindel 10 percent owner YERUSHALAYIM ROAD 34, BEIT GAMLA ENTRANCE B, RA'ANANA L3 4350110
I.b.f. Management Ltd. 10 percent owner 4 OPPENHEIMER ST., REHOVOT L3 7670104
Igor Gitelman officer: Chief Accounting Officer 201 ROUTE 17 N., 2ND FLOOR, RUTHERFORD NJ 07070

Advaxis (Advaxis) Headlines

From GuruFocus

Advaxis, Inc. Announces 1-for-80 Reverse Stock Split

By GuruFocusNews GuruFocusNews 06-03-2022

Advaxis Announces Publication of ADXS-PSA Data in The Oncologist

By GuruFocusNews GuruFocusNews 04-08-2022